

Anti-inflammatory activity of new 1,3,4-oxadiazole derivatives

Banylla Felicity Dkhar Gatphoh, Natasha Naval Aggarwal, Hemanth Kumar, B. C. Revanasiddappa

Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences of Nitte-Deemed to be University, Mangalore, Karnataka, India

Corresponding Author:

B. C. Revanasiddappa, Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences of Nitte-Deemed to be University, Mangalore, Karnataka, India. E-mail: revan@nitte.edu.in

Received: Jan 01, 2021 Accepted: Feb 22, 2021 Published: Dec 04, 2021

ABSTRACT

A new series of 1,3,4-oxadiazole derivatives **(3a-j)** were synthesized by reacting p-toluic benzhydrazide **(1)** and substituted aromatic aldehydes **(2)** in the presence of ceric ammonium nitrate as catalyst and dichloromethane as a solvent medium. The structures of the new compounds were assigned based on IR, ¹H-NMR, and mass spectral data and further evaluated for their *in vitro* anti-inflammatory potential using various protein denaturation methods following bovine serum and egg albumin assay. Some tested compounds **3e**, **3f**, **and 3i** displayed moderate anti-inflammatory activity compared to the standard diclofenac sodium.

Keywords: 1,3,4-Oxadiazole, anti-inflammatory, benzhydrazide, bovine albumin, ceric ammonium nitrate

INTRODUCTION

Hereocyclic compounds are a promising area for synthetic study as well as biological activity. Oxadiazole, a fivemembered aromatic ring, is found to be an essential class of heterocyclic compounds. These azoles are composed of oxygen and nitrogen atoms of the general formula C₂H₂ON₂. 1,3,4-oxadiazoles are the leading class of compounds in the area of discovery of drugs due to their vast pharmacological activities such as anticancer,^[1] antioxidant,^[2] anti-arthritic,^[3] antibacterial,^[4] analgesic,^[5] anticonvulsant,^[6] and anti-HIV^[7]. Moreover, five-membered heterocyclic rings containing nitrogen, carbon, or oxygen at the symmetrical position have been studied deliberately for their various biological activities.^[8]

Most of the 1,3,4-oxadiazole derivatives have a significant role in medicinal chemistry. Some of the medicinally essential compounds which are composed of this moiety are raltegravir (HIV-integrase inhibitor drug), fenadiazole (Hypnotic), zibotentan (anticancer), tiodazosin (alpha1-adrenergic antagonist), and furamizole (nitrofuran antibacterial).

Inflammation is the immune system's response to irritants. These irritants can be harmful stimuli or toxic compounds, germs, or damaged cells involving in the accumulation of cells exuding in irritated tissues instigating the healing process.^[9] As time follows, inflammation has been considered an effort to fight its impact on the body.^[10]

Anti-inflammatory drugs (NSAIDs) have been reported in the market such as indomethacin, Ibuprofen, fenoprofen,

fenbufen, and diclofenac, which are the derivatives of propionic acid and acetic acid. However, their clinical uses have been limited by the risk of its gastrointestinal toxicity reported due to the direct proximity of free carboxylic acid with gastrointestinal mucosa, leading to the hindrance of non-selective cyclooxygenase enzyme.^[11-15]

1,3,4-oxadiazoles are usually synthesized using carbohydrazides, Schiff bases, and diacylhydrazines. Many oxidizing agents/cyclizing agents are available for their synthesis, namely, phosphorus oxy chloride,^[16] iodo benzene diacetate,^[17] FeCl₃,^[18] ceric ammonium nitrate (CAN),^[19] chloramine-T,^[20] mercuric oxide/iodine, etc.^[21]

With the emerging broad spectrum of activities, 1,3,4-oxadiazole draws heedless attention to the researcher. However, after further monitoring and studying the pharmacophore of 1,3,4-oxadiazole, we distinct to synthesize different analogs due to its substitution at the second and the fifth position of the oxadiazole ring.

MATERIALS AND METHODS

All chemicals, including p-toluic benzhydrazide, and solvents were procured from Sigma-Aldrich, Bengaluru, India. The open capillary tube method was employed for determining the melting points. Thin-layer chromatography was used to check the reaction progress using plates of aluminum silica gel 60 F_{245} . The spots were observed under the ultraviolet light chamber. Alpha Bruker FT-IR-Spectrometer was used for recording IR spectra (cm⁻¹). Bruker Avance-II NMR spectrometer (USA) was employed to record

¹H-NMR spectra operating at 400 MHz with dimethyl sulfoxide (5%)/CDCl_a as a solvent where TMS served as an internal standard. The recording of the mass spectra was carried out by PerkinElmer gas chromatography-mass spectrometry (USA).

Synthesis of 1,3,4-Oxadiazole Derivatives (3a-j)

p-toluic benzhydrazide (1) (0.01M) and substituted aromatic aldehydes (2) (0.01M) were dissolved in dichloromethane (30 ml). A pinch of CAN was added, and the contents were refluxed for 10-14 h and cooled to room temperature. The crude product obtained was filtered, washed with water, dried, and recrystallized using alcohol. The physical data of title compounds 1,3,4-oxadiazoles (3a- j) are given in Table 1.

2-(4-bromophenyl)-5-p-tolyl-1,3,4-oxadiazole(3a)

C₁₅H₁₁BrN₂O. Mol. wt.: 315.16. % Yield: 72. M.P: 185–187°C. FT-IR (KBr, cm⁻¹): 1090 (C-O-C), 1555 (C=C), 1628 (C=N), 3028 (C-H). ¹H-NMR (CDCl₂): δ 2.51 (s, CH₂, 3H), 7.33-8.43 (m, Ar-H, 8H). LC–MS: m/z: 315.16(M⁺).

2-(4-nitrophenyl)-5-p-tolyl-1,3,4-oxadiazole(3b)

C₁₅H₁₁N₂O₂ Mol. wt.: 281.27. %Yield: 68. M.P:190–192°C. FT-IR (KBr, cm⁻¹): 1079 (C-O-C), 1527 (C=C), 1632 (C=N), 3049 (C-H). ¹H-NMR (CDCl₂): δ 2.39 (s, CH₃, 3H), 7.34–8.57 (m, Ar-H, 8H). LC-MS: m/z:281.27 (M⁺).

2-(4-chlorophenyl)-5-p-tolyl-1,3,4-oxadiazole(3c)

C., H., ClN, O Mol. wt.: 270.71. %Yield: 64. M.P: 255-257°C FT-IR (KBr, cm⁻¹): 1071 (C-O-C), 1555 (C=C), 1629 (C=N), 3047 (C-H).1H-NMR (CDCl3): δ 2.38 (s, CH3, 3H), 7.32–8.45 (m, Ar-H, 8H). LC-MS: m/z: 270.71(M+1).

N,N-dimethyl-4-(5-p-tolyl-1,3,4-oxadiazol-2-yl)aniline(3d)

C., H., N.O Mol. wt.: 279.34. %Yield: 76. M.P: 230-232°C. FT-IR (KBr, cm⁻¹): 1097(C-O-C), 1555 (C=C), 1606 (C=N), 3003 (C-H). ¹H-NMR (CDCl₂): δ 2.51 (s, CH₂, 3H), 2.98 (s, 2XCH₂, 6H), 7.33-8.43 (m, Ar-H, 8H). LC-MS: m/z: 279.34(M⁺).

2-(3,4-dimethoxyphenyl)-5-p-tolyl-1,3,4-oxadiazole(3e)

C₁₇H₁₄N₂O₂Mol. wt.: 296.32. % Yield: 74. M.P: 228–230°C. FT-IR (KBr, cm⁻¹): 1099 (C-O-C), 1545 (C=C), 1628 (C=N), 3007 (C-H). ¹H-NMR (CDCl₂): δ 2.48 (s, CH₂, 3H), 3.36 (s, 2XOCH₂,

| Table 1: Physical of 1,3,4-oxadiazole derivatives (3 | 3a-j) |
|--|-------|
|--|-------|

7H), 7.47–7.81 (m, Ar-H, 7H). LC–MS: m/z: 296.32(M⁺).

4-(5-p-tolyl-1,3,4-oxadiazol-2-yl) phenol (3f)

C1. H1. N2O2 Mol. wt.: 252.27. % Yield: 69. M.P: 210-212°C. FT-IR (KBr, cm⁻¹): 1066 (C-O-C), 1525 (C=C), 1601 (C=N), 3057 (C-H). 3401 (OH). ¹H-NMR (CDCl₂): δ 2.50 (s, CH₂, 3H), 6.75– 8.31 (m, Ar-H, 8H), 11.47(s, OH, 1H).LC-MS: m/z: 252.27 (M⁺).

2-(5-p-tolyl-1,3,4-oxadiazol-2-yl) phenol (3g)

C₁₅H₁₉N₂O₂ Mol. wt.: 252.27. %Yield: 68. M.P: 205–207°C. FT-IR (KBr, cm⁻¹): 1081 (C-O-C), 1526 (C=C), 1608 (C=N), 3077 (C-H). 3439 (OH). ¹H-NMR (CDCl₂): δ 2.38 (s, CH₂, 3H), 6.83-8.34 (m, Ar-H, 8H), 11.57 (s, OH, 1H). LC-MS: m/z:252.27 (M⁺).

2-phenyl-5-p-tolyl-1,3,4-oxadiazole(3h)

C₁, H₁, N₂O Mol. wt.: 236.27. % Yield: 75. M.P: 216–218°C. FT-IR (KBr, cm⁻¹): 1023 (C-O-C), 1541 (C=C), 1602 (C=N), 3059 (C-H). ¹H-NMR (CDCl₂): δ 2.39 (s, CH₂, 3H), 6.91–9.64 (m, Ar-H, 8H). LC-MS: m/z:236.27 (M⁺).

2-(4-methoxyphenyl)-5-p-tolyl-1,3,4-oxadiazole(3i)

C₁₆H₁₄N₂O₂ Mol. wt.: 266.29. % Yield: 77. M.P: 246–248°C. FT-IR (KBr, cm⁻¹): 1098(C-O-C), 1554 (C=C), 1626 (C=N), 3051 (C-H). ¹H-NMR (CDCl₂): δ 2.50 (s, CH₂, 3H), 3.81 (s, OCH₂, 3H), 7.62-8.39 (m, Ar-H, 8H). LC-MS: m/z: 266.29 (M+).

2-(4-fluorophenyl)-5-p-tolyl-1,3,4-oxadiazole(3j)

C₁, H₁, FN₂O Mol. wt.: 254.26. % Yield: 67. M.P: 263–265°C. FT-IR (KBr, cm⁻¹): 1083 (C-O-C), 1561 (C=C), 1630 (C=N), 3032 (C-H). ¹H-NMR (CDCl₂): δ 2.38 (s, CH₂, 3H), 7.28-8.45 (m, Ar-H, 8H). LC-MS: m/z: 254.26 (M⁺).

Hydrazones can be mediated in synthesis of 1,3,4-oxadiazoles by cyclization -oxidation reaction by using CAN as catalyst using DCM as solvent. The possible mechanism is depicted in the following Figure 1.^[22]

In vitro Anti-inflammatory Activity

Bovine serum albumin denaturation assay^[23]

About 5% w/v aqueous solution of serum bovine albumin was prepared. Test solution (0.5 mL) was prepared using 0.05 mL of different concentrations (10-50 µg/mL) of synthesized

| Table 1: Physical | of 1,3,4-oxadiazole de | rivatives (3a-J) | | | |
|-------------------|--|---|----------------------------|-------------------------------|----------------|
| Compound | R-CHO | Molecular formula | Molecular weight | MP (°C) | Yield (%) |
| 3a | 4-Br | $C_{15}H_{11}BrN_2O$ | 315.16 | 185–187 | 72 |
| 3b | $4-NO_2$ | $C_{15}H_{11}N_{3}O_{3}$ | 281.27 | 190–192 | 68 |
| 3c | 4-Cl | $C_{15}H_{11}ClN_2O$ | 270.71 | 255-257 | 64 |
| 3d | 4-N $(CH_3)_2$ | $C_{17}H_{17}N_{3}O$ | 279.34 | 230-232 | 76 |
| 3e | 3,4-(OCH ₃) ₂ | $C_{17}H_{16}N_2O_3$ | 296.32 | 228-230 | 74 |
| 3f | 4-OH | $C_{15}H_{12}N_2O_2$ | 252.27 | 210-212 | 69 |
| 3g | 2-OH | $C_{15}H_{12}N_2O_2$ | 252.27 | 205-07 | 68 |
| 3h | C_6H_5 | $C_{15}H_{12}N_{2}O$ | 236.27 | 216-218 | 75 |
| 3i | 4-OCH ₃ | $C_{16}H_{14}N_2O_2$ | 266.29 | 246-248 | 77 |
| 3j | 4-F | $\mathrm{C_{15}H_{11}FN_{2}O}$ | 254.26 | 263–265 | 67 |
| 3h 3i 3j | C ₆ H ₅ 4-OCH ₃ 4-F | $C_{15}H_{12}N_2O$ $C_{16}H_{14}N_2O_2$ $C_{15}H_{11}FN_2O$ | 236.27 266.29 254.26 | 216–218 246–248 263–265 | 75 77 67 |



Figure 1: Mechanism involved in the reaction

compounds (3a-j) and 0.45 mL of bovine serum albumin and was mixed thoroughly. 0.45 mL of the 5% w/v aqueous solution of serum bovine albumin, that is, 5%w/v, along with 0.05 mL of distilled H₂O, was used as a control solution. 0.05 mL of test compounds (3a-j) along with 0.45 mL of distilled water is taken as the product control. 0.05 mL of diclofenac sodium and 0.45 mL of the 5% w/v aqueous solution of serum bovine albumin were taken as a standard. 1 N HCl was prepared and use to adjust the pH of the above solutions, that is, test, control, product control, and standard to pH 6.3. The above solutions were incubated at 37°C for 20 min, further heated for 3 min at 57°C. 2.5 mL of phosphate buffer was added after the incubation period to the above solution, and the absorbance was read at 416 nm using an ELISA plate reader. All the tests were carried out in triplicates. The results of the bovine serum albumin denaturation assay (3aj) are shown in Table 2. Percentage inhibition of denaturation was expressed as IC_{50} (μ M) (Figure 2). Percentage inhibition of denaturation was calculated using the formula.

% inhibition = $100 \times [Vt/Vc-1]$

Egg albumin Denaturation Assay^[23]

A 5 ml of test solution consists of egg albumin (0.2 ml) prepared from hen's egg and different concentrations (10–50 µg/ml) of test compounds **(3a-j)**. A 5 ml of the control solution consists of 0.2 ml of egg albumin and distilled H₂O. A 5 ml of the standard solution consists of different concentrations of diclofenac sodium (2 ml and 0.2 ml of egg albumin). A 2 ml phosphate buffer of pH 6.4 is added to both the control, test solution, and standard solution. The above solution was incubated at $37 \pm 2^{\circ}$ C for 15 min, further heated at 70°C for 5 min. The absorbance was measured at 660 nm using an ELISA plate reader. All the tests were carried out in triplicates. The results of the egg albumin denaturation assay (3a-j) are shown in Table 3. Percentage inhibition of denaturation was expressed as IC₅₀ (μ M) (Figure 3). Percentage inhibition of denaturation was calculated using the formula.

% inhibition =
$$100 \times [Vt/Vc-1]$$



Figure 2: Bovine serum albumin assay



Figure 3: Egg albumin denaturation assay

RESULTS AND DISCUSSION

Chemistry

In the present work, a new series of 1,3,4-oxadiazoles **(3a-j)** were synthesized using CAN as an oxidative catalyst. The outline of the work is depicted in **Scheme 1.** p-toluic benzhydrazide **(1)** was employed as a starting material to synthesize 1,3,4-oxadiazole analogs substituted at the second and fifth position of the oxadiazole ring. The hydrazide was made to react with different

| Table 2: Data | a of bovine serum | albumin denatu | ration assay of co | mpounds (3a-j) | | | | | | | |
|----------------------|-------------------|------------------|--------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Con. | | | | | Percen | tage inhibition | no | | | | |
| | Std. | 3a | 3b | 3с | 3d | 3e | 3f | 3g | 3h | 3i | 3j |
| 10 μg/ml | 17.70 ± 0.12 | $13.54{\pm}0.18$ | 13.54 ± 0.03 | 9.375±0.44 | 25 ± 0.26 | 7.29 ± 0.32 | 9.37 ± 0.42 | 9.37±0.27 | 27.08 ± 0.43 | 16.66 ± 0.33 | 20.83 ± 0.22 |
| 20 μg/ml | 20.83 ± 0.08 | 15.62 ± 0.23 | 20.83 ± 0.34 | 12.5 ± 0.32 | 38.54 ± 0.22 | 19.79 ± 0.35 | 20.83 ± 0.32 | 19.79 ± 0.10 | 38.54 ± 0.38 | 20.83 ± 0.36 | 29.16 ± 0.32 |
| 30 μg/ml | 62.50 ± 0.23 | 20.83 ± 0.32 | 30.20 ± 0.43 | 32.29 ± 0.07 | 40.62 ± 0.34 | 20.83 ± 0.44 | 33.33 ± 0.24 | 30.20 ± 0.18 | 40.62 ± 0.50 | 32.29 ± 0.27 | 40.62 ± 0.43 |
| 40 μg/ml | 76.04 ± 0.21 | 32.29 ± 0.29 | 41.66 ± 0.28 | 43.75 ± 0.22 | 51.04 ± 0.42 | 35.41 ± 0.54 | 43.75 ± 0.27 | 40.62 ± 0.23 | 51.04 ± 0.47 | 42.70 ± 0.19 | 51.04 ± 0.39 |
| 50 μg/ml | 79.16 ± 0.36 | $47.9\ 1\pm0.23$ | 47.91 ± 0.02 | 53.12 ± 0.32 | 64.58 ± 0.21 | 64.58 ± 0.28 | 56.25 ± 0.30 | 48.95 ± 0.32 | 64.58±0.44 | 66.66 ± 0.15 | 64.58 ± 0.34 |
| $IC_{50z}(\mu g/ml)$ | 19.29 ± 0.20 | 48.04 ± 0.24 | 41.39 ± 0.19 | 36.66 ± 0.22 | 54.54 ± 0.28 | 35.68 ± 0.22 | 34.82 ± 0.31 | 40.20 ± 0.19 | 57.14 ± 0.33 | 31.62 ± 0.17 | 45.71 ± 0.35 |
| IC_{50} (μ M) | 0.061 ± 0.20 | 0.152 ± 0.24 | 0.147 ± 0.19 | 0.135 ± 0.22 | 0.195 ± 0.28 | 0.120 ± 0.22 | 0.138 ± 0.31 | 0.159 ± 0.19 | 0.242 ± 0.33 | 0.119 ± 0.17 | 0.180 ± 0.35 |
| | | | | | | | | | | | |

| (3a- |
|--------------|
| compounds |
| of |
| assay |
| denaturation |
| albumin |
| serum |
| of bovine |
| Data |
| ä |
| e |
| ē |

Table 3: Data of egg albumin denaturation assay of compounds (3a-j)

| 0000 | | | | | C. POR | ididai onotao | 400 | | | | |
|--------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| conc. | | | | | Pero | centage innibi | non | | | | |
| | Std. | 3a | 3b | 3с | 3d | Зе | 3f | 3g | 3h | 3i | 3j |
| 10 µg/ml | 20.83 ± 0.32 | 18.75 ± 0.40 | 32.29 ± 0.26 | 30.20 ± 0.43 | 30.21 ± 0.08 | 12.5 ± 0.23 | 16.66 ± 0.06 | 19.79 ± 0.15 | 9.37 ± 0.16 | 32.29 ± 0.19 | 8.33 ± 0.28 |
| 20 μg/ml | 53.12 ± 0.43 | 30.20 ± 0.24 | 35.41 ± 0.18 | 32.29 ± 0.32 | 34.37 ± 0.26 | 32.2 ± 0.44 | 22.91 ± 0.23 | 25.00 ± 0.33 | 15.6 ± 0.17 | 43.75 ± 0.24 | 18.75 ± 0.11 |
| 30 µg/ml | 62.5 ± 0.34 | 28.12 ± 0.13 | 45.83 ± 0.25 | 43.75 ± 0.37 | 38.54 ± 0.12 | 41.66 ± 0.37 | 47.91 ± 0.42 | 27.08 ± 0.12 | 23.9 ± 0.13 | 42.70 ± 0.32 | 32.29 ± 0.21 |
| 40 µg/ml | 64.58 ± 0.13 | 41.66 ± 0.16 | 66.66 ± 0.22 | 64.58 ± 0.18 | 59.37 ± 0.27 | 54.16 ± 0.23 | 54.16 ± 0.18 | 41.66 ± 0.34 | 25.0 ± 0.54 | 43.75 ± 0.34 | 33.33 ± 0.43 |
| 50 µg/ml | 68.75 ± 0.19 | 42.70 ± 0.20 | 67.70±0.09 | 69.79 ± 0.33 | 64.58 ± 0.27 | 64.58 ± 0.28 | 58.33 ± 0.22 | 55.20 ± 0.30 | 41.66 ± 0.41 | 68.75 ± 0.39 | 37.5 ± 0.41 |
| IC ₅₀ (µg/ml) | 16.31 ± 0.21 | 49.82 ± 0.24 | 48.97 ± 0.14 | 44.85 ± 0.26 | 53.33 ± 0.32 | 27.10 ± 0.12 | 28.72 ± 0.21 | 38.57 ± 0.29 | 56.33 ± 0.33 | 25.14 ± 0.21 | 52.85 ± 0.27 |
| IC ₅₀ (μM) | 0.051 ± 0.21 | 0.158 ± 0.24 | 0.174 ± 0.14 | 0.166 ± 0.26 | 0.191 ± 0.32 | 0.091 ± 0.12 | 0.114 ± 0.21 | 0.153 ± 0.29 | 0.238 ± 0.33 | 0.094 ± 0.21 | 0.208 ± 0.27 |
| | | | | | | | | | | | |



Scheme 1: Synthetic scheme of 1,3,4-oxadiazole derivatives

substituted aromatic aldehydes **(2)**, which undergo selective cyclization in the presence of cerium ammonium nitrate (CAN) as a catalytic medium and dichloromethane as a solvent to furnish the formation of final 1,3,4-oxadiazole derivatives. Dichloromethane acts as an excellent solvent medium and CAN as a tenable and uncontaminated catalytic agent. The purity of the compounds was ascertained by TLC and recrystallization techniques. The physicochemical data of the synthesized compounds are listed in Table 1. All the synthesized compounds were acquired in good yields between 64% and 77%.

The postulated structures of the 1,3,4-oxadiazoles were confirmed by FT-IR, ¹H-NMR, and mass spectral data. The FT-IR spectrum of compound **3a** showed an absorption band at 3028 cm⁻¹ attributed to the C-H stretching. The other stretching vibrations at 1628 and 1555 cm⁻¹ correspond to C=N and C=C groups, respectively. The absence of the carbonyl group of the hydrazide in the region of 1640–1680 cm⁻¹ clearly indicates the oxadiazole ring formation. Formation of the compound **3a** was further confirmed by the ¹H-NMR spectrum, wherein the presence of aromatic protons was observed in the region of $\delta7.33-8.43$ ppm. A sharp singlet was observed at $\delta2.51$ ppm, indicating the presence of methyl protons. Further, the molecular ion peak at 315.16 [M+] in the mass spectrum of the compound confirmed the proposed structure.

Biological Evaluation

Denaturation of proteins is a well-reported cause of Inflammation; hence, the denaturation of egg and bovine serum albumin by the synthesized analogs of 1,3,4-oxadiazole was demonstrated as an attempt to evaluate its anti-inflammatory potential.

In the assay of bovine serum albumin method, all the tested compounds exhibited moderate-to-weak inhibitory efficacy at a concentration of 10–50 µg/ml. Compounds **3c**, **3e**, **3f**, **and 3i** showed moderate inhibition, compared to the standard drug (diclofenac sodium) at their micromolar concentrations. Compounds **3c** and **3f** showed moderate inhibition at the same micromolar concentration, that is, 0.13 µM. Furthermore, compounds **3e** and **3i** showed moderate inhibition at a concentration of 0.12 µM. This may be attributed due to the presence of electron-donating groups, which are present at the third/fourth position of the aromatic ring. All the other tested compounds showed very weak activity [Table 2].

In the case of egg serum albumin denaturation assay, most of the tested compounds exhibited moderate activity when compared to the standard diclofenac sodium. Compounds **3e, 3i, and 3f** showed moderate activity, and it is due to the presence of electron-donating groups such as methoxy and hydroxyl at position fourth [Table 3]. These compounds showed activity at low micromolar levels (0.091, 0.094, and 0.114, respectively) when compared to the other tested compounds. All the other compounds showed very weak activity in comparison to the standard.

From both activity profiles, it is clear that only those compounds with electron-donating capacity are exhibiting moderate activity, while the electron-withdrawing groups are showing weak activity toward the protein denaturation assay.

CONCLUSION

A new series of disubstituted 1,3,4-oxadiazoles at the second and fifth positions were synthesized, and spectral data confirmed their structures. Compounds with electron-donating groups showed moderate inhibitory anti-inflammatory activity in both the tested methods. CAN is an effective catalyst in the synthesis of proposed title compounds. It offers many advantages like available in solid form, non-irritant, reaction conditions are simple, easy to handle, a specific product, excellent yield, without any side products, compared to other oxidative/cyclizing agents.

ACKNOWLEDGMENTS

The authors are thankful to the authorities of NGSM Institute of Pharmaceutical Sciences, Nitte-Deemed to be University, Mangalore, for providing all the necessary facilities. The authors are thankful to Vellore Institute of Technology, Vellore, for providing NMR and mass spectral data.

REFERENCES

- Aboraia AS, Abdel-Rahman HM, Mahfouz NM, El-Gendy MA. Novel 5-(2-hydroxyphenyl)-3-substituted-2, 3-dihydro-1, 3, 4-oxadiazole-2-thione derivatives: Promising anticancer agents. Bioorg Med Chem 2006;14:1236-46.
- 2. Musad EA, Mohamed R, Saeed BA, Vishwanath BS, Rai KL. Synthesis and evaluation of antioxidant and antibacterial activities of new substituted bis (1, 3, 4-oxadiazoles), 3, 5-bis (substituted) pyrazoles and isoxazoles. Bioorg Med Chem Lett 2011;21:3536-40.
- 3. Gatphoh BF, Revanasiddappa BC, Kumar MV, Kumar H. Synthesis, anti-arthritic and antioxidant activities of novel 1, 3, 4-oxadiazole derivatives. Synthesis, anti-arthritic and antioxidant activities of

novel 1,3,4-oxadiazole derivatives. Ind Drugs 2018;55:18-23.

- 4. Maslat AO, Abussaud M, Tashtoush H, AL-Talib M. Synthesis, antibacterial, antifungal and genotoxic activity of bis-1, 3, 4-oxadiazole derivatives. Polish J Pharmacol 2002;54:55-60.
- Bhandari SV, Bothara KG, Raut MK, Patil AA, Sarkate AP, Mokale VJ. Design, synthesis and evaluation of anti-inflammatory, analgesic and ulcerogenicity studies of novel S-substituted phenacyl-1, 3, 4-oxadiazole-2-thiol and Schiff bases of diclofenac acid as nonulcerogenic derivatives. Bioorg Med Chem 2008;16:1822-31.
- 6. Almasirad A, Vousooghi N, Tabatabai SA, Kebriaeezadeh A, Shafiee A. Synthesis, anticonvulsant and muscle relaxant activities of substituted 1, 3, 4-oxadiazole, 1, 3, 4-thiadiazole and 1, 2, 4-triazole. Acta Chim Slovenica 2007;54:317-24.
- Hajimahdi Z, Zarghi A, Zabihollahi R, Aghasadeghi MR. Synthesis, biological evaluation, and molecular modeling studies of new 1, 3, 4-oxadiazole-and 1, 3, 4-thiadiazole-substituted 4-oxo-4H-pyrido [1, 2-a] pyrimidines as anti-HIV-1 agents. Med Chem Res 2013;22:2467-75.
- Lohani M, Parthsarthy R. Synthesis, characterization and antiinflammatory activity of some 1, 3,4-oxadiazole derivatives. Iran J Pharm Res 2013;12:319-23.
- 9. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, *et al*. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018;9:7204-18.
- 10. Yuan G, Wahlqvist ML, He G, Yang M, Li D. Natural products and anti-inflammatory activity. Asia Pac J Clin Nutr 2006;15:143-52.
- 11. Bushra R, Aslam N. An overview of clinical pharmacology of Ibuprofen. Oman Med J 2010;25:155-1661.
- Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. New Eng J Med 1992;327:749-54.
- 13. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK.

Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radi Bio Med 2007;42:706-19.

- Crossley RJ. Side effect and safety data for fenbufen. The Am J Med 1983;75:84-90.
- Nalamachu S, Wortmann R. Role of indomethacin in acute pain and inflammation management: A review of the literature. Postgrad Med 2014;126:92-7.
- Revanasiddappa BC, Subrahmanyam EV, Satyanarayana D. Synthesis and biological evaluation of 2-aryl-5(8-quinolonoxymethyl) 1, 3, 4-oxadiazoles. Ind J Het Chem 2009;18:403-4.
- 17. Prasanna KB, Mohana KN, Mallesha L. Synthesis of N-[{5-Aryl-1,3,4-oxadiazole-2-yl}methyl]-4-methoxyaniline derivatives and their anticonvulsant activity. J Chem 2013;2013:121029.
- Babak K, Foad KM, Pirouz AB, Khoshkhoo AB, Jun-Ya K, Yokomatsu T. Iron(III) Chloride/L-proline as an efficient catalyst for the synthesis of 3-substituted 1,2,4-oxadiazoles from amidoximes and triethyl orthoformate. Synthesis 2016;48:3597-602.
- 19. Mazaahir K, Divya B, Neeraj KM. Polyethylene glycol (PEG) mediated green synthesis of 2,5-disubstituted 1,3,4-oxadiazoles catalyzed by ceric ammonium nitrate (CAN). Green Chem Letter Review 2010;3:5559-64.
- 20. Revanasiddappa BC, Subrahmanyam EV. Chloramine-T mediated synthesis of 1, 3, 4-oxadiazoles. Oriental J Chem 2009;25:707-10.
- 21. Ishwarbhat K, Revanasiddappa BC, Prems J, Mumtaz MH. Synthesis and biological evaluation of some novel 1,3,4-oxadiazole derivatives. Ind J Het Chem 2011;21:288-9.
- 22. Behalo MS. An efficient one-pot catalyzed synthesis of 2, 5-disubstituted-1, 3, 4-oxadiazoles and evaluation of their antimicrobial activities. RSC Adv 2016;6:103132-6.
- 23. Rahman MH, Eswaraiah C, Dutta AM. *In-vitro* anti-inflammatory and anti-arthritic activity of *Oryza sativa* var. joha rice (an aromatic indigenous rice of Assam), American-Eurasian. J Agric Environ Sci 2015;15:115-21.